Literature DB >> 19958055

Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis?

Pentti Sipponen1, Matti Härkönen.   

Abstract

Malabsorption of dietary calcium is a cause of osteoporosis. Dissolution of calcium salts (e.g. calcium carbonate) in the stomach is one step in the proper active and passive absorption of calcium as a calcium ion (Ca(2+)) in the proximal small intestine. Stomach acid markedly increases dissolution and ionization of poorly soluble calcium salts. If acid is not properly secreted, calcium salts are minimally dissolved (ionized) and, subsequently, may not be properly and effectively absorbed. Atrophic gastritis, gastric surgery, and high-dose, long-term use of antisecretory drugs markedly reduce acid secretion and may, therefore, be risk conditions for malabsorption of dietary and supplementary calcium, and may thereby increase the risk of osteoporosis in the long term.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19958055     DOI: 10.3109/00365520903434117

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  29 in total

1.  Serologically Determined Gastric Mucosal Condition Is a Predictive Factor for Osteoporosis in Japanese Men.

Authors:  Shigeto Mizuno; Daisuke Matsui; Isao Watanabe; Etsuko Ozaki; Nagato Kuriyama; Yoshiyuki Watanabe
Journal:  Dig Dis Sci       Date:  2015-02-08       Impact factor: 3.199

2.  Proton pump inhibitors: use, misuse and concerns about long-term therapy.

Authors:  T P Rakesh
Journal:  Clin J Gastroenterol       Date:  2011-02-18

Review 3.  The role of the gastrointestinal tract in calcium homeostasis and bone remodeling.

Authors:  J Keller; T Schinke
Journal:  Osteoporos Int       Date:  2013-03-28       Impact factor: 4.507

4.  Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats.

Authors:  Kerstin Stemmer; Maximilian Bielohuby; Bernadette E Grayson; Denovan P Begg; Adam P Chambers; Christina Neff; Stephen C Woods; Reinhold G Erben; Matthias H Tschöp; Martin Bidlingmaier; Thomas L Clemens; Randy J Seeley
Journal:  Endocrinology       Date:  2013-04-03       Impact factor: 4.736

5.  Assessment of the presence and quality of osteoporosis prevention education among at-risk internal medicine patients.

Authors:  Jennifer A Shulha; Cortney B Sviggum; John G O'Meara; Melody L Berg
Journal:  Consult Pharm       Date:  2014-01

Review 6.  Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

7.  Primary hyperparathyroidism after Roux-en-Y gastric bypass.

Authors:  Yufei Chen; Carrie C Lubitz; Scott A Shikora; Richard A Hodin; Randall D Gaz; Francis D Moore; Travis J McKenzie
Journal:  Obes Surg       Date:  2015-04       Impact factor: 4.129

8.  Recalcitrant hypocalcemia after thyroidectomy in patients with previous Roux-en-Y gastric bypass.

Authors:  Travis J McKenzie; Yufei Chen; Richard A Hodin; Scott A Shikora; Matthew M Hutter; Randall D Gaz; Francis D Moore; Carrie C Lubitz
Journal:  Surgery       Date:  2013-08-23       Impact factor: 3.982

Review 9.  Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers.

Authors:  Lars Agréus; Ernst J Kuipers; Limas Kupcinskas; Peter Malfertheiner; Francesco Di Mario; Marcis Leja; Varocha Mahachai; Niv Yaron; Martijn van Oijen; Guillermo Perez Perez; Massimo Rugge; Jukka Ronkainen; Mikko Salaspuro; Pentti Sipponen; Kentaro Sugano; Joseph Sung
Journal:  Scand J Gastroenterol       Date:  2012-02       Impact factor: 2.423

10.  Is gastrectomy-induced high turnover of bone with hyperosteoidosis and increase of mineralization a typical osteomalacia?

Authors:  Takashi Ueyama; Yuta Yamamoto; Kazuki Ueda; Aiji Yajima; Yoshimasa Maeda; Yasunobu Yamashita; Takao Ito; Yoshihiro Tsuruo; Masao Ichinose
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.